Congressional Hearing Intensifies Scrutiny on Pharmacy Benefit Managers
Lawmakers from both parties challenge PBMs on practices that allegedly inflate drug prices and limit patient options.
Overview
- House Oversight Committee criticizes PBMs for steering patients toward higher-priced medications.
- Executives from major PBMs defend their role, blaming drug manufacturers for high costs.
- New bipartisan bill aims to increase transparency and reform PBM practices.
- Report alleges PBMs are moving operations overseas to avoid regulatory scrutiny.
- FTC plans to sue major PBMs over their business practices.